DynamiCure

Edit info

Founded: 2020

Location: Waltham, MA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Solid tumors

Drug types: ONC

Lead product: DCBY02

Funding: not disclosed

dynamicure.com

linkedin.com

job board

Drug notes:

DCSZ11 Clin0 oncology

About:

DynamiCure is developing therapies to treat cancer, autoimmune and other diseases. Due to dysfunctional vasculature, the tumor microenvironment (TME) is often hypoxic and immunosuppressive. By normalizing the tumor vasculature, it is thought that the TME will switch to be immunostimulatory, facilitating the infiltration of immune cells. DynamiCure’s lead program, DC-6001, interferes with the CD93 pathway and is hoped to switch the TME from an immunosuppressive to an immunostimulatory environment. CD93 is a novel receptor target identified as being involved in vascular growth control. The program consists of two anti-CD93 monoclonal antibodies and DynamiCure are enrolling patients with a range of advanced cancers for Phase 1 clinical trials.